Scientists track cancer Drug's journey through the body
NCT ID NCT05109832
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial studied how healthy men absorb, process, and eliminate the experimental cancer drug IMP4297. Six Chinese male volunteers took a single radioactive-labeled dose so researchers could track the drug's path. The goal was to understand the drug's metabolism and excretion, not to test its effectiveness against tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IMP4297 (a radioactive-labeled drug being studied for solid tumors)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?